Member area login

You don't have or don't remember the password!
Click Here

Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da M. Visconti

Valutazione molecolare nella leucemia mieloide cronica
Molecular monitoring in chronic myeloid leukemia (CML)
A. Galdiero \| B. Izzo \| R. Accetta \| S. Caruso \| B. De Angelis \| C. Del Prete \| S. Errichiello \| G. Muccioli Casadei \| F. Musella \| C. Quintarelli \| M. Visconti \| F. Pane \|
<p>The pathognomonic genetic alteration in CML is the formation of the BCR-ABL fusion gene, which produces a constitutively active tyrosine kinase that drives leukemic transformation. Targeted tyrosine kinase inhibitor treatment is the cornerstone of modern therapy for this hematologic malignancy. Analysis of BCR-ABL [through reverse transcriptase-quantitative polymerase chain reaction (RT-QPCR)] is the gold standard approach for quantitatively assessing minimal residual disease and monitoring the efficacy of tyrosine kinase inhibitor therapy in CML patients. The continuous therapeutic improvement has led to increasingly ambitious treatment endpoints, which, in turn, require more and more refined measurement and definition of molecular response levels. For these reasons standardization efforts of monitoring by RT-QPCR are now focused on ensuring reliable and harmonized expression of quantitative results.</p>
Biochimica Clinica ; 39(2) 094-099 Rassegne - Reviews

Flow citometry for screening acute urinary tract infections and differentiation between Gram positive and Gram negative bacteria

G. Saccani \| G. Gessoni \| S. Valverde \| F. Manoni \| M. Visconti \|
<p>Urine culture is the most frequent test in microbiology laboratories. A screening tool, providing fast and reliable results to rule-out urinary tract infection (UTI), would be of great importance. We studied 1043 consecutive urine samples by Sysmex UF-1000i analyzer. Comparison was made by robotic urine culture on chromogenic agar with 1 μL loop, using 10<sup>5</sup> CFU/mL as a limit of positive growth. We evaluated bacteria quantification for rapid exclusion of UTI and bacteria forward scatter (B_FSC) in preliminary discrimination of UTI caused by Gram positive or Gram negative bacteria. For exclusion of UTI, the best cut-off value was 130 bacteria/μL. At this threshold, the sensitivity (SE) was 0.98 and the specificity (SP) 0.75. For exclusion of UTI sustained by Gram positive bacteria, the best cut-off value for B_FSC was 25ch. At this threshold, SE was 0.68 and SP was 0.89.</p>
Biochimica Clinica ; 38(6) 625-629 Contributi scientifici - Scientific Papers